United States

FDA approves OTC Oxytrol for Women for overactive bladder

Monday, January 28, 2013 10:53 AM

The FDA has approved Merck’s Oxytrol for Women, the first over-the-counter treatment for overactive bladder in women ages 18 years and older. Oxytrol will remain available for men with overactive bladder by prescription only.

More... »

Salk Institute awarded $42M from Helmsley Charitable Trust

Monday, January 28, 2013 09:55 AM

The Salk Institute for Biological Studies, a San Diego-based institute focused both on discovery and on mentoring future generations of researchers, has received a $42 million gift from The Leona M. and Harry B. Helmsley Charitable Trust to establish the Helmsley Center for Genomic Medicine (HCGM).

More... »

DIA names Stephen P. Spielberg editor-in-chief of TIRS journal

Friday, January 25, 2013 11:59 AM

DIA, a neutral, global, professional and member-driven association of nearly 18,000 professionals, announced the arrival of Stephen P. Spielberg, M.D., Ph.D., as editor-in-chief of the newly launched, official DIA peer-reviewed scientific journal, Therapeutic Innovation & Regulatory Science (TIRS).

More... »

Variance makes growth investment in Veristat

Friday, January 25, 2013 09:56 AM

Holliston, Mass.-based CRO Veristat said Variance Development Partners, a private investment group focused on contributing growth capital to small to mid-sized firms serving developing pharmaceutical and medical device companies, has made a growth equity investment in the company.

More... »

Foundation Medicine expands Series B financing to $56M

Wednesday, January 23, 2013 03:07 PM

Foundation Medicine, a Cambridge Mass.-based molecular information company, has expanded its Series B financing, raising an additional $13.5 million and bringing the total raised in the round to $56 million. The new investors include Bill Gates, Evan Jones and Yuri Milner.

More... »

Allergan to acquire MAP Pharmaceuticals

Wednesday, January 23, 2013 12:18 PM

Allergan and MAP Pharmaceuticals, both based in California, have jointly announced a definitive merger agreement whereby Allergan will acquire 100% of MAP Pharmaceuticals shares for $25 per share. MAP Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new therapies in neurology, including Levadex, an orally inhaled drug for the potential acute treatment of migraine in adults which is currently is under review with the FDA.

More... »

Invacare completes sale of medical supplies business to AssuraMed

Wednesday, January 23, 2013 10:56 AM

Invacare, an Elyria, Ohio-based manufacturer and distributor of home and long-term care medical products, has completed the sale of its Invacare Supply Group (ISG) medical supplies business to AssuraMed, a medical supply distributor based in Twinsburg, Ohio, for a purchase price of approximately $150.8 million in cash.

More... »

Versartis closes $25M Series C financing

Wednesday, January 16, 2013 10:24 AM

Versartis, an emerging biotechnology company focused on endocrine disorders, has completed a $25 million Series C financing lead by new investor Aisling Capital. The primary use of the proceeds will be to fund clinical trials of its lead product, VRS-317, for growth hormone deficiency (GHD) in pediatric patients. VRS-317 is a proprietary once monthly form of recombinant human growth hormone (rhGH).

More... »

Velocity Pharmaceutical announces clinical development agreement

Wednesday, January 16, 2013 09:55 AM

Velocity Pharmaceutical Development, is a pharmaceutical development organization, has signed a licensing agreement to pursue a drug development program utilizing EuMederis Pharmaceuticals' EuPort technology for optimizing the pharmaceutical properties of peptide drugs.

More... »

ActiGraph launches ActiLife Mobile app

Tuesday, January 15, 2013 10:32 AM

Pensacola, Fla.-based ActiGraph, a provider of objective patient monitoring solutions for the global research community, has released a new mobile app for researchers.

More... »